We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The World Health Organization (WHO) has recommended the use of interleukin-6 receptor blockers — including Roche’s Actemra (tocilizumab) and Sanofi’s Kevzara (sarilumab) — plus corticosteroids for the treatment of severe COVID-19. Read More
CureVac’s messenger-RNA (mRNA)-based COVID-19 vaccine, CVnCoV, was just 48 percent effective in a final analysis from a late-stage trial ― one percentage point higher than reported in an earlier phase 3 analysis and still below the FDA’s 50 percent efficacy threshold required for Emergency Use Authorization. Read More
The European Medicines Agency (EMA) has issued a list of five preferred therapeutics for COVID-19 patients, including four monoclonal antibodies and Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib). Read More
A third shot of AstraZeneca’s COVID-19 vaccine used as a booster prompts a strong immune response, including against variant strains of the SARS-CoV-2 virus, Oxford University researchers reported yesterday. Read More
HHS has stopped shipping Eli Lilly’s COVID-19 antibody cocktail (bamlanivimab/etesevimab) because of the therapy’s lack of effectiveness against new variants of SARS-CoV-2. Read More
Two U.S. House committees are broadening their investigation into Emergent BioSolutions’ troubled Bayview, Md., facility, calling on Johnson & Johnson (J&J) and AstraZeneca (AZ) to provide details of their COVID-19 vaccine contracts with the firm. Read More
A Centers for Disease Control and Prevention (CDC) expert panel yesterday concluded that there is likely a link between heart inflammation and inoculations with the Pfizer/BioNTech and Moderna COVID-19 vaccines but emphasized that the benefits of the shots greatly outweigh the risks. Read More